How much funding has Acrivon Therapeutics raised?

Acrivon Therapeutics has raised $230.0M in total funding, most recently a Venture Round.

Who are Acrivon Therapeutics's investors?

Acrivon Therapeutics's investors include Morgan Stanley, Jefferies, Cowen, Piper Sandler, Wellington Management, Surveyor Capital.

When was Acrivon Therapeutics founded?

Acrivon Therapeutics was founded in 2018.

Where is Acrivon Therapeutics headquartered?

Acrivon Therapeutics is headquartered in Watertown, Massachusetts, United States.

What industry is Acrivon Therapeutics in?

Acrivon Therapeutics operates in Biotech.

How many employees does Acrivon Therapeutics have?

Acrivon Therapeutics has 51-200 employees.

Acrivon Therapeutics

IPO

Precision oncology powered by proteomics

Public · Watertown, United States · Founded 2018 · $230.0M raised

Biotech

Headquarters: Watertown, Massachusetts
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: acrivon.com

Total Funding: $230.0M
Last Round: $130.0M Venture RoundApr 2024
Rounds: 2
Type: Public

About

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary Acrivon Precision Predictive Proteomics (AP3) platform. The AP3 platform enables unprecedented patient selection by profiling the activity of key cancer-driving proteins at the individual tumor level, identifying which patients are most likely to respond to a given targeted therapy. Headquartered in Watertown, Massachusetts, Acrivon is advancing a pipeline of precision oncology drug candidates, including ACR-368, a CHK1/2 inhibitor being evaluated in endometrial and ovarian cancers.

Summary

Acrivon Therapeutics is a Biotech company based in Watertown, United States, founded in 2018. It has raised $230.0M in total across 2 rounds, most recently a $130.0M Venture Round round in Apr 2024. Investors include Morgan Stanley, Jefferies and Cowen.